TY - JOUR
T1 - Diabetes and COVID-19 risk
T2 - an miRNA perspective
AU - Mishra, Paras K.
AU - Tandon, Ritesh
AU - Byrareddy, Siddappa N.
N1 - Funding Information:
This work was supported, in part, by National Institutes of Health (NIH) Grants HL-113281 and 1U54GM115458 and the University of Nebraska Medical Center for Heart and Vascular Research (to P.K.M.); National Aeronautics and Space Administration Grant 80NSSC19K1603 and the University of Mississippi Medical Center COVID-19 Fund (to R.T.); and NIH Grant P30MH062261 and Frances E. Lageschulte and Evelyn B. Weese New Frontiers in Medical Research Fund (to S.N.B.).
Publisher Copyright:
Copyright © 2020 the American Physiological Society
PY - 2020/9
Y1 - 2020/9
N2 - Coronavirus disease 2019 (COVID-19) and diabetes outcomes (CORONADO) trial revealed that 10.6% of patients with diabetes mellitus hospitalized for COVID-19 (COVID-19) die within 7 days. Several studies from New York, Italy, and China confirm that patients with diabetes are at a much higher risk for mortality due to COVID-19. Besides respiratory illness, COVID-19 increases cardiac injury and diabetic ketoacidosis. In the absence of specific guidelines for the prevention and treatment of COVID-19 for patients with diabetes, they remain at higher risk and are more susceptible to COVID-19. Furthermore, there is a scarcity of basic knowledge on how diabetes affects pathogenesis of severe acute respiratory coronavirus (SARSCoV-2) infection. In patients with diabetes, impaired glucose use alters metabolic and consequently biological processes instigating pathological remodeling, which has detrimental effects on cardiovascular systems. A majority of biological processes are regulated by noncoding microRNAs (miRNAs), which have emerged as a promising therapeutic candidate for several diseases. In consideration of the higher risk of mortality in patients with diabetes and COVID-19, novel diagnostic test and treatment strategy are urgently warranted in post-COVID-19 era. Here, we describe potential roles of miRNA as a biomarker and therapeutic candidate, especially for heart failure, in patients with diabetes and COVID-19.
AB - Coronavirus disease 2019 (COVID-19) and diabetes outcomes (CORONADO) trial revealed that 10.6% of patients with diabetes mellitus hospitalized for COVID-19 (COVID-19) die within 7 days. Several studies from New York, Italy, and China confirm that patients with diabetes are at a much higher risk for mortality due to COVID-19. Besides respiratory illness, COVID-19 increases cardiac injury and diabetic ketoacidosis. In the absence of specific guidelines for the prevention and treatment of COVID-19 for patients with diabetes, they remain at higher risk and are more susceptible to COVID-19. Furthermore, there is a scarcity of basic knowledge on how diabetes affects pathogenesis of severe acute respiratory coronavirus (SARSCoV-2) infection. In patients with diabetes, impaired glucose use alters metabolic and consequently biological processes instigating pathological remodeling, which has detrimental effects on cardiovascular systems. A majority of biological processes are regulated by noncoding microRNAs (miRNAs), which have emerged as a promising therapeutic candidate for several diseases. In consideration of the higher risk of mortality in patients with diabetes and COVID-19, novel diagnostic test and treatment strategy are urgently warranted in post-COVID-19 era. Here, we describe potential roles of miRNA as a biomarker and therapeutic candidate, especially for heart failure, in patients with diabetes and COVID-19.
KW - Biomarker
KW - Cardiovascular disease
KW - Heart failure
KW - Noncoding RNA
KW - SARS-CoV-2
KW - Therapeutic candidate
UR - http://www.scopus.com/inward/record.url?scp=85090054271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090054271&partnerID=8YFLogxK
U2 - 10.1152/ajpheart.00489.2020
DO - 10.1152/ajpheart.00489.2020
M3 - Review article
C2 - 32762561
AN - SCOPUS:85090054271
SN - 0363-6135
VL - 319
SP - H604-H609
JO - American Journal of Physiology - Heart and Circulatory Physiology
JF - American Journal of Physiology - Heart and Circulatory Physiology
IS - 3
ER -